Information  X 
Enter a valid email address

Ergomed plc (ERGO)

  Print   

Wednesday 18 August, 2021

Ergomed plc

Director dealings

RNS Number : 0540J
Ergomed plc
18 August 2021
 

 

Director Dealings

 

 

Guildford, UK - 18 August 2021 : Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, announces that on 17 August 2021, in order to meet demand from new and existing investors, Dr Miroslav Reljanović, Executive Chairman of Ergomed, and Richard Barfield, Chief Financial Officer of Ergomed, sold 1,200,000 ordinary shares of 1p each in the Company ("Ordinary Shares") and 50,000 Ordinary Shares respectively at a price of 1200 pence per share.

 

Following these sales, Dr Miroslav Reljanović holds 9,679,297 Ordinary Shares representing 19.8% of the Company's issued share capital and Richard Barfield holds 50,000 Ordinary Shares representing 0.1% of the Company's issued share capital.

 

The relevant notifications set out below are provided in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Miroslav Reljanović

2

Reason for the notification

a)

Position/status

Executive Chairman

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Sale of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£12.00

1,200,000



e)

Aggregated information

 

- Aggregated volume

 

- Price

 

- Aggregated total

 

 

 

1,200,000

 

£12.00

 

£14,400,000

 

 

f)

Date of the transaction

17 August 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Barfield

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Ergomed plc

b)

Legal Entity Identifier

213800BVS8I9VMC1AP84

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

 GB00BN7ZCY67

b)

Nature of the transaction

Sale of Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

£12.00

50,000



e)

Aggregated information

 

- Aggregated volume

 

- Price

 

- Aggregated total

 

 

 

50,000

 

£12.00

 

£600,000

 

 

f)

Date of the transaction

17 August 2021

g)

Place of the transaction

London Stock Exchange, AIM

 

ENDS

 

Enquiries :

 

Ergomed plc     Tel: +44 (0) 1483 402 975

Miroslav Reljanović (Executive Chairman) 

Richard Barfield (Chief Financial Officer) 

 

Numis Securities Limited    Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Matthew O'Dowd (Nominated Adviser) 

James Black (Broker) 

 

Peel Hunt LLP    Tel: +44 (0) 20 7418 8900

James Steel / Dr. Christopher Golden

 

Consilium Strategic Communications   Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal   [email protected]

Angela Gray

 

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand and a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO). For further information, visit: http://ergomedplc.com .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUQURUPGGGR

a d v e r t i s e m e n t